Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M112,511Revenue (TTM) $M22,562Net Margin (%)33.6Altman Z-Score2.7
Enterprise Value $M109,854EPS (TTM) $10.0Operating Margin %41.4Piotroski F-Score8
P/E(ttm)15.1Beneish M-Score-2.5Pre-tax Margin (%)39.0Higher ROA y-yY
Price/Book3.710-y EBITDA Growth Rate %11.8Quick Ratio4.1Cash flow > EarningsY
Price/Sales5.15-y EBITDA Growth Rate %17.6Current Ratio4.4Lower Leverage y-yY
Price/Free Cash Flow14.5y-y EBITDA Growth Rate %16.8ROA % (ttm)10.2Higher Current Ratio y-yN
Dividend Yield %2.6PEG0.9ROE % (ttm)26.1Less Shares Outstanding y-yY
Payout Ratio %38.0Shares Outstanding M744ROIC % (ttm)28.5Gross Margin Increase y-yY

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNKen Fisher 2016-12-31 Add$135.22 - $168.31
($150.5)
$ 152.721%Add 19.79%123,139
AMGNMartin Whitman 2016-10-31 Add0.24%$141.16 - $175.62
($168.51)
$ 152.72-9%Add 14.92%139,400
AMGNVanguard Health Care Fund 2016-09-30 Reduce-0.78%$154.27 - $175.62
($169.1)
$ 152.72-10%Reduce -46.83%2,759,552
AMGNJoel Greenblatt 2016-09-30 Reduce-0.4%$154.27 - $175.62
($169.1)
$ 152.72-10%Reduce -44.60%269,204
AMGNFirst Eagle Investment 2016-09-30 Reduce-0.22%$154.27 - $175.62
($169.1)
$ 152.72-10%Reduce -60.50%369,976
AMGNGeorge Soros 2016-09-30 Buy 0.02%$154.27 - $175.62
($169.1)
$ 152.72-10%New holding3,506
AMGNMario Gabelli 2016-09-30 Reduce-0.02%$154.27 - $175.62
($169.1)
$ 152.72-10%Reduce -38.27%22,425
AMGNThird Avenue Management 2016-09-30 Reduce-0.01%$154.27 - $175.62
($169.1)
$ 152.72-10%Reduce -1.04%134,226
AMGNRichard Pzena 2016-09-30 Buy $154.27 - $175.62
($169.1)
$ 152.72-10%New holding1,196
AMGNDodge & Cox 2016-09-30 Reduce$154.27 - $175.62
($169.1)
$ 152.72-10%Reduce -2.67%40,157
AMGNKen Fisher 2016-09-30 Add$154.27 - $175.62
($169.1)
$ 152.72-10%Add 1.20%102,794
AMGNMartin Whitman 2016-07-31 Buy 1.85%$144.58 - $172.03
($156.46)
$ 152.72-2%New holding121,300
AMGNThird Avenue Management 2016-06-30 Buy 0.92%$144.58 - $164.35
($155.39)
$ 152.72-2%New holding135,642
AMGNJoel Greenblatt 2016-06-30 Add0.3%$144.58 - $164.35
($155.39)
$ 152.72-2%Add 50.26%485,933
AMGNFirst Eagle Investment 2016-06-30 Reduce-0.11%$144.58 - $164.35
($155.39)
$ 152.72-2%Reduce -24.17%936,565
AMGNVanguard Health Care Fund 2016-06-30 Reduce-0.02%$144.58 - $164.35
($155.39)
$ 152.72-2%Reduce -0.98%5,190,355
AMGNKeeley Asset Management Corp 2016-06-30 Buy 0.01%$144.58 - $164.35
($155.39)
$ 152.72-2%New holding1,325
AMGNMario Gabelli 2016-06-30 Reduce$144.58 - $164.35
($155.39)
$ 152.72-2%Reduce -2.38%36,325
AMGNDodge & Cox 2016-06-30 Reduce$144.58 - $164.35
($155.39)
$ 152.72-2%Reduce -5.28%41,257
AMGNKen Fisher 2016-06-30 Reduce$144.58 - $164.35
($155.39)
$ 152.72-2%Reduce -9.87%101,573
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Such Annette LouiseVP, Finance and CAO 2016-08-02Sell3,000$174.59-12.53view
Balachandran MadhavanEVP, Operations 2016-05-04Sell30,000$154.12-0.91view
Harper Sean EEVP, Research & Development 2016-04-29Sell21,875$157.99-3.34view
BALTIMORE DAVIDDirector 2016-04-29Sell3,312$157.21-2.86view
Bradway Robert AChairman, CEO and President 2016-03-02Sell20,000$146.484.26view
de Carbonnel FrancoisDirector 2015-08-31Sell5,000$153.84-0.73view
Hassan FredDirector 2015-08-19Buy3,010$166.63-8.35view
PELHAM JUDITH CDirector 2015-07-31Sell5,035$180.4-15.34view
Patton Cynthia MSVP & CCO 2015-06-02Sell4,530$157.06-2.76view
Balachandran MadhavanEVP, Operations 2015-05-07Sell21,750$157.87-3.26view

Press Releases about AMGN :

Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    AbbVie Increases Price of Humira Jan 23 2017 
    Boehringer Ingelheim's Humira Biosimilar Under Review by EMA and FDA Jan 19 2017 
    Mean Reversion and the Bell Curve Jan 03 2017 
    Amgen: Opportunity May Be Knocking Dec 31 2016 
    Third Avenue Value Fund Buys 2 Stocks and Adds to 2 Positions in Q4 Dec 23 2016 
    6 Worthy Dividend Stocks Down 10% or More Nov 22 2016 
    AbbVie Reports 3rd Quarter Results Nov 01 2016 
    Martin Whitman's Top Recent Investments Oct 12 2016 
    FDA Approval of Amjevita Need Not Worry AbbVie Shareholders Sep 28 2016 
    Whitman's Third Avenue Buys 3 Pharma Stocks in 3rd Quarter Sep 27 2016 

    More From Other Websites
    Gilead Clobbered On Hep C; 'Little Value' In 'Too Late' NASH, HIV Units Jan 23 2017
    Can Q4 Earnings Revitalize Healthcare ETFs? Jan 23 2017
    Should Amgen, Inc. (AMGN) Be In Your Portfolio? Jan 23 2017
    Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017 Jan 23 2017
    Amgen Could Gouge 'Top Pick' AbbVie With Humira Biosimilar: Jefferies Jan 20 2017
    3 Stocks Ripe for a Big Rebound in 2017 Jan 19 2017
    Can Amgen (AMGN) Be a Top Choice for Value Investors? Jan 19 2017
    Gilead 2017 Outlook Hamstrung On Hep C, But RBC Bullish On Amgen, Biogen Jan 18 2017
    Orphan Drugs Among 2015's Top 10 Best-Selling Medications Jan 18 2017
    Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad Jan 17 2017
    deCODE Study Shows that Variants in the Sequence of the Genome that Contribute to Educational... Jan 17 2017
    Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink Jan 13 2017
    Trump's 'Disastrous' Pharma View Doesn't Rattle JPMorgan Drug Conference Jan 13 2017
    [$$] Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs Jan 13 2017
    Supreme Court to hear a variety of business-related to ca... Jan 13 2017
    Amgen Fight Over Copies of Biotech Drugs Gets High Court Review Jan 13 2017
    Amgen, Inc. : AMGN-US: Dividend Analysis : November 16th, 2016 (record date) : By the numbers :... Jan 12 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)